Does DABIGATRAN ETEXILATE Cause Malignant neoplasm progression? 32 Reports in FDA Database
Lower Your Cholesterol — The Natural Way
The Oxidized Cholesterol Strategy: a science-backed plan for heart health.
According to the FDA Adverse Event Reporting System (FAERS), 32 reports of Malignant neoplasm progression have been filed in association with DABIGATRAN ETEXILATE (dabigatran etexilate). This represents 0.1% of all adverse event reports for DABIGATRAN ETEXILATE.
32
Reports of Malignant neoplasm progression with DABIGATRAN ETEXILATE
0.1%
of all DABIGATRAN ETEXILATE reports
15
Deaths
19
Hospitalizations
How Dangerous Is Malignant neoplasm progression From DABIGATRAN ETEXILATE?
Of the 32 reports, 15 (46.9%) resulted in death, 19 (59.4%) required hospitalization, and 2 (6.3%) were considered life-threatening.
Is Malignant neoplasm progression Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for DABIGATRAN ETEXILATE. However, 32 reports have been filed with the FAERS database.
What Other Side Effects Does DABIGATRAN ETEXILATE Cause?
Gastrointestinal haemorrhage (4,081)
Cerebrovascular accident (2,175)
Fall (1,786)
Ischaemic stroke (1,581)
Anaemia (1,412)
Haemorrhage (1,324)
Death (1,025)
Rectal haemorrhage (964)
Cerebral haemorrhage (946)
Upper gastrointestinal haemorrhage (861)
What Other Drugs Cause Malignant neoplasm progression?
PEMBROLIZUMAB (10,111)
NIVOLUMAB (9,363)
ENZALUTAMIDE (4,696)
CARBOPLATIN (4,177)
EVEROLIMUS (3,789)
PACLITAXEL (3,484)
LETROZOLE (3,445)
IPILIMUMAB (3,296)
FULVESTRANT (3,221)
LENVATINIB (2,929)
Which DABIGATRAN ETEXILATE Alternatives Have Lower Malignant neoplasm progression Risk?
DABIGATRAN ETEXILATE vs DABRAFENIB
DABIGATRAN ETEXILATE vs DABRAFENIB\TRAMETINIB
DABIGATRAN ETEXILATE vs DACARBAZINE
DABIGATRAN ETEXILATE vs DACLATASVIR
DABIGATRAN ETEXILATE vs DACLIZUMAB